The asset-swap between GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) will lead to stronger focus by both companies on their current core activities. The transaction sets a new framework for future complex deals, where participants enhance their operations by divesting from non-profitable divisions, while acquiring assets that enhance the current portfolios. GSK’s position in vaccines … Continue reading GLAXOSMITHKLINE & NOVARTIS SWAP ASSTES WORTH £11BN
Bocconi Students M&A Circle 